Publication
Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerUveal Melanomacivic_curation1.00
- drugSelumetinibcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneMETcivic_curation1.00
- variantMET Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25952648
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB3 Overexpression1 | ||||||||
| Selumetinib + TrametinibSubstitutes | Uveal Melanoma | Predictive | D | Supports Resistance | 4 | submitted | EID3050MEK inhibitors improve survival in cutaneous melanoma patients but show only modest efficacy in metastatic uveal melanoma patients. In this study, we screened for growth factors that elicited resistan… (full text at CIViC) PMID 25952648 · Cheng et al., 2015 · Open in CIViC | civic |
| MET Overexpression2 | ||||||||
| C-Met Inhibitor + ERBB3 Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Uveal Melanoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID3037MEK inhibitors improve survival in cutaneous melanoma patients but show only modest efficacy in metastatic uveal melanoma patients. In this study, we screened for growth factors that elicited resistan… (full text at CIViC) PMID 25952648 · Cheng et al., 2015 · Open in CIViC | civic |
| Selumetinib + TrametinibSubstitutes | Uveal Melanoma | Predictive | D | Supports Resistance | 3 | accepted | EID3038In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib,… (full text at CIViC) PMID 25952648 · Cheng et al., 2015 · Open in CIViC | civic |